Genetic causation of neointimal hyperplasia in hemodialysis vascular access dysfunction

Seminars in Dialysis

Volumn 25, Issue 1, 2012, Pages 65-73

  Lee, Timmy ^a,b,c   Wadehra, Davinder ^a,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ARTERIOVENOUS SHUNT; CHRONIC KIDNEY FAILURE; EQUIPMENT; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; HYPERPLASIA; INDWELLING CATHETER; INSTRUMENTATION; METHODOLOGY; NEOINTIMA; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; RENAL REPLACEMENT THERAPY; REVIEW; VASCULAR DISEASE;

ARTERIOVENOUS SHUNT, SURGICAL; CATHETERS, INDWELLING; EQUIPMENT FAILURE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERPLASIA; KIDNEY FAILURE, CHRONIC; NEOINTIMA; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASES; POLYMORPHISM, GENETIC; RENAL DIALYSIS; RNA, MESSENGER; VASCULAR DISEASES;

EID: 84856290247     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00967.x     Document Type: Review

References (146)

1. Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA: Hemodialysis vascular access morbidity in the United States. Kidney Int 43:1091-1096, 1993.
2. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 7:523-535, 1996.
3. Roy-Chaudhury P, Sukhatme VP, Cheung AK: Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 17:1112-1127, 2006.
4. Roy-Chaudhury P, Lee TC: Vascular stenosis: biology and interventions. Curr Opin Nephrol Hypertens 16:516-522, 2007.
5. Lee T, Roy-Chaudhury P: Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis 16:329-338, 2009.
6. Rao M, Jaber BL, Balakrishnan VS: Gene polymorphism association studies in dialysis: cardiovascular disease. Semin Dial 18:217-225, 2005.
7. Balakrishnan VS, Rao M, Jaber BL: Genomic medicine, gene polymorphisms, and human biological diversity. Semin Dial 18:37-40, 2005.
8. Bell J: The new genetics in clinical practice. BMJ 316:618-620, 1998.
9. Collins FS: Shattuck lecture-medical and societal consequences of the Human Genome Project. N Engl J Med 341:28-37, 1999.
10. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, et al.: Initial sequencing and analysis of the human genome. Nature 409:860-921, 2001.
11. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Altshuler D: A map of human genome sequence variation containing 1.42million single nucleotide polymorphisms. Nature 409:928-933, 2001.
12. Vasan RS: Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113:2335-2362, 2006.
13. McKusick VA, Ruddle FH: Toward a complete map of the human genome. Genomic 1:103-106, 1987.
14. Broeckel U, Hengstenberg C, Mayer B, Holmer S, Martin LJ, Comuzzie AG, Blangero J, Nurnberg P, Reis A, Riegger GA, Jacob HJ, Schunkert H: A comprehensive linkage analysis for myocardial infarction and its related risk factors. Nat Genet 30:210-214, 2002.
15. Harrap SB, Zammit KS, Wong ZY, Williams FM, Bahlo M, Tonkin AM, Anderson ST: Genome-wide linkage analysis of the acute coronary syndrome suggests a locus on chromosome 2. Arterioscler Thromb Vasc Biol 22:874-878, 2002.
16. Hauser ER, Crossman DC, Granger CB, Haines JL, Jones CJ, Mooser V, McAdam B, Winkelmann BR, Wiseman AH, Muhlestein JB, Bartel AG, Dennis CA, Dowdy E, Estabrooks S, Eggleston K, Francis S, Roche K, Clevenger PW, Huang L, Pedersen B, Shah S, Schmidt S, Haynes C, West S, Asper D, Booze M, Sharma S, Sundseth S, Middleton L, Roses AD, Hauser MA, Vance JM, Pericak-Vance MA, Kraus WE: A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study. Am J Hum Genet 75:436-447, 2004.
17. Fox CS, Yang Q, Cupples LA, Guo CY, Larson MG, Leip EP, Wilson PW, Levy D: Genomewide linkage analysis to serum creatinine, GFR, and creatinine clearance in a community-based population: the Framingham Heart Study. J Am Soc Nephrol 15:2457-2461, 2004.
18. Craig DW, Millis MP, DiStefano JK: Genome-wide SNP genotyping study using pooled DNA to identify candidate markers mediating susceptibility to end-stage renal disease attributed to Type 1 diabetes. Diabet Med 26:1090-1098, 2009.
19. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40:1185-1192, 2008.
20. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40:1175-1184, 2008.
21. Kottgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, Yang Q, Gudnason V, Launer LJ, Harris TB, Smith AV, Arking DE, Astor BC, Boerwinkle E, Ehret GB, Ruczinski I, Scharpf RB, Idagw YD, de Boer IH, Haritunians T, Lumley T, Sarnak M, Siscovick D, Benjamin EJ, Levy D, Upadhyay A, Aulchenko YS, Hofman A, Rivadeneira F, Uitterlinden AG, van Duijn CM, Chasman DI, Pare G, Ridker PM, Kao WH, Witteman JC, Coresh J, Shlipak MG, Fox CS: Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 41:712-717, 2009.
22. Behar DM, Rosset S, Tzur S, Selig S, Yudkovsky G, Bercovici S, Kopp JB, Winkler CA, Nelson GW, Wasser WG, Skorecki K: African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Hum Mol Genet 19:1816-1827, 2010.
23. Seo D, Wang T, Dressman H, Herderick EE, Iversen ES, Dong C, Vata K, Milano CA, Rigat F, Pittman J, Nevins JR, West M, Goldschmidt-Clermont PJ: Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol 24:1922-1927, 2004.
24. Nordfors L, Lindholm B, Stenvinkel P: End-stage renal disease-not an equal opportunity disease: the role of genetic polymorphisms. J Intern Med 258:1-12, 2005.
25. Bowden DW, Colicigno CJ, Langefeld CD, Sale MM, Williams A, Anderson PJ, Rich SS, Freedman BI: A genome scan for diabetic nephropathy in African Americans. Kidney Int 66:1517-1526, 2004.
26. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, et al.: The sequence of the human genome. Science 291:1304-1351, 2001.
27. Lander ES, Schork NJ: Genetic dissection of complex traits. Science 265:2037-2048, 1994.
28. Carlson CS, Eberle MA, Kruglyak L, Nickerson DA: Mapping complex disease loci in whole-genome association studies. Nature 429:446-452, 2004.
29. Altmuller J, Palmer LJ, Fischer G, Scherb H, Wjst M: Genomewide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet 69:936-950, 2001.
30. Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science 273:1516-1517, 1996.
31. Chakravarti A: Population genetics-making sense out of sequence. Nat Genet 21:56-60, 1999.
32. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33:177-182, 2003.
33. Reich DE, Lander ES: On the allelic spectrum of human disease. Trends Genet 17:502-510, 2001.
34. Hirschhorn JN: Genomewide association studies-illuminating biologic pathways. N Engl J Med 360:1699-1701, 2009.
35. Kottgen A: Genome-wide association studies in nephrology research. Am J Kidney Dis 56:743-775, 2010.
36. Stenvinkel P: Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 19:53-61, 2001.
37. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38:1408-1413, 2001.
38. Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Ortiz M, Tagle R, Gonzalez F, Quiroga T, Caceres MS, Leighton F, Pereira J: Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 60:1844-1850, 2001.
39. Kaysen GA: The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 12:1549-1557, 2001.
40. Girndt M, Heine GH, Ulrich C, Kohler H: Gene polymorphism association studies in dialysis: vascular access. Semin Dial 20:63-67, 2007.
41. Stracke S, Konner K, Kostlin I, Friedl R, Jehle PM, Hombach V, Keller F, Waltenberger J: Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int 61:1011-1019, 2002.
42. Ram S, Bass K, Abreo K, Baier RJ, Kruger TE: Tumor necrosis factor-alpha -308 gene polymorphism is associated with synthetic hemodialysis graft failure. J Investig Med 51:19-26, 2003.
43. Rees LE, Wood NA, Gillespie KM, Lai KN, Gaston K, Mathieson PW: The interleukin-10-1082G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci 59:560-569, 2002.
44. Ozaki K, Leonard WJ: Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem 277:29355-29358, 2002.
45. Sung SA, Ko GJ, Jo SK, Cho WY, Kim HK, Lee SY: Interleukin-10 and tumor necrosis factor-alpha polymorphisms in vascular access failure in patients on hemodialysis: preliminary data in Korea. J Korean Med Sci 23:89-93, 2008.
46. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV: Genotypic variation in the transforming growth factor-beta 1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66:1014-1020, 1998.
47. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV: Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol 6:193-197, 1998.
48. Heine GH, Ulrich C, Sester U, Sester M, Kohler H, Girndt M: Transforming growth factor beta 1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int 64:1101-1107, 2003.
49. Motwani JG, Topol EJ: Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97:916-931, 1998.
50. Lim PS, Hung WR, Wei YH: Polymorphism in methylenetetrahydrofolate reductase gene: its impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving hemodialysis. Nephron 87:249-256, 2001.
51. Haviv YS, Shpichinetsky V, Goldschmidt N, Atta IA, Ben-Yehuda A, Friedman G: The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients. Nephron 92:120-126, 2002.
52. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP: An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 60:1106-1113, 2001.
53. McCully KS: Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann Clin Lab Sci 39:219-232, 2009.
54. McCully KS: Homocysteine and vascular disease. Nat Med 2:386-389, 1996.
55. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al.: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113, 1995.
56. Fukasawa M, Matsushita K, Kamiyama M: The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis 41:637-642, 2003.
57. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC: Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 78:225-230, 1996.
58. Radomski MW, Palmer RM, Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2:1057-1058, 1987.
59. Basaran O, Atac FB, Karakayali F, Aliosmanoglu I, Yagmurdur MC, Ozdemir FN, Haberal M: Endothelial nitric oxide synthase gene intron 4 (VNTR) polymorphism and vascular access graft thrombosis. J Invest Surg 20:49-53, 2007.
60. Arking DE, Becker DM, Yanek LR, Fallin D, Judge DP, Moy TF, Becker LC, Dietz HC: KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 72:1154-1161, 2003.
61. Nagai R, Saito Y, Ohyama Y, Aizawa H, Suga T, Nakamura T, Kurabayashi M, Kuroo M: Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci 57:738-746, 2000.
62. Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC: Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res 96:412-418, 2005.
63. Kim Y, Jeong SJ, Lee HS, Kim EJ, Song YR, Kim SG, Oh JE, Lee YK, Seo JW, Yoon JW, Koo JR, Kim HJ, Noh JW, Park SH: Polymorphism in the promoter region of the klotho gene (G-395A) is associated with early dysfunction in vascular access in hemodialysis patients. Korean J Intern Med 23:201-207, 2008.
64. Sies H: Oxidative stress: oxidants and antioxidants. Exp Physiol 82:291-295, 1997.
65. Himmelfarb J, Hakim RM: Oxidative stress in uremia. Curr Opin Nephrol Hypertens 12:593-598, 2003.
66. Lin CC, Yang WC, Lin SJ, Chen TW, Lee WS, Chang CF, Lee PC, Lee SD, Su TS, Fann CS, Chung MY: Length polymorphism in heme oxygenase-1 is associated with arteriovenous fistula patency in hemodialysis patients. Kidney Int 69:165-172, 2006.
67. Durante W: Heme oxygenase-1 in growth control and its clinical application to vascular disease. J Cell Physiol 195:373-382, 2003.
68. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839, 2003.
69. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516, 2001.
70. Ye S, Gale CR, Martyn CN: Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J 24:1668-1671, 2003.
71. Vasku A, Goldbergova M, Izakovicova Holla L, Siskova L, Groch L, Beranek M, Tschoplova S, Znojil V, Vacha J: A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biol 22:585-591, 2004.
72. Schwarz A, Haberbosch W, Tillmanns H, Gardemann A: The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis Markers 18:121-128, 2002.
73. Hirashiki A, Yamada Y, Murase Y, Suzuki Y, Kataoka H, Morimoto Y, Tajika T, Murohara T, Yokota M: Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol 42:1429-1437, 2003.
74. Terashima M, Akita H, Kanazawa K, Inoue N, Yamada S, Ito K, Matsuda Y, Takai E, Iwai C, Kurogane H, Yoshida Y, Yokoyama M: Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 99:2717-2719, 1999.
75. Zhou X, Huang J, Chen J, Su S, Chen R, Gu D: Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing Atherosclerosis Study. Thromb Haemost 92:867-873, 2004.
76. Humphries SE, Martin S, Cooper J, Miller G: Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet 66:343-352, 2002.
77. deMaat MP, Jukema JW, Ye S, Zwinderman AH, Moghaddam PH, Beekman M, Kastelein JJ, van Boven AJ, Bruschke AV, Humphries SE, Kluft C, Henney AM: Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 83:852-856, 1999.
78. Gnasso A, Motti C, Irace C, Carallo C, Liberatoscioli L, Bernardini S, Massoud R, Mattioli PL, Federici G, Cortese C: Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 20:1600-1605, 2000.
79. Lin CC, Yang WC, Chung MY, Lee PC: Functional polymorphisms in matrix metalloproteinases-1, -3, -9 are associated with arteriovenous fistula patency in hemodialysis patients. Clin J Am Soc Nephrol 5:1805-1814, 2010.
80. Roy-Chaudhury P, Arend L, Zhang J, Krishnamoorthy M, Wang Y, Banerjee R, Samaha A, Munda R: Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis 50:782-790, 2007.
81. Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, Heffelfinger SC: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 59:2325-2334, 2001.
82. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68:450-456, 1991.
83. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245:186-188, 1989.
84. O'Donohoe MK, Schwartz LB, Radic ZS, Mikat EM, McCann RL, Hagen PO: Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts. Ann Surg 214:727-732, 1991.
85. Isbir CS, Akgun S, Yilmaz H, Civelek A, Ak K, Tekeli A, Agachan B, Cobanoglu A: Is there a role of angiotensin-converting enzyme gene polymorphism in the failure of arteriovenous femoral shunts for hemodialysis? Ann Vasc Surg 15:443-446, 2001.
86. Heine GH, Ulrich C, Kohler H, Girndt M: Is AV fistula patency associated with angiotensin-converting enzyme (ACE) polymorphism and ACE inhibitor intake? Am J Nephrol 24:461-468, 2004.
87. Bonnici F, Keavney B, Collins R, Danesh J: Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies. BMJ 325:517-520, 2002.
88. Chen M, Masaki T, Sawamura T: LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 95:89-100, 2002.
89. de Knijff P, van den Maagdenberg AM, Frants RR, Havekes LM: Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mutat 4:178-194, 1994.
90. Ilveskoski E, Perola M, Lehtimaki T, Laippala P, Savolainen V, Pajarinen J, Penttila A, Lalu KH, Mannikko A, Liesto KK, Koivula T, Karhunen PJ: Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 100:608-613, 1999.
91. Kwon HM, Hong BK, Kang TS, Kwon K, Kim HK, Jang Y, Choi D, Park HY, Kang SM, Cho SY, Kim HS: Expression of osteopontin in calcified coronary atherosclerotic plaques. J Korean Med Sci 15:485-493, 2000.
92. Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240:622-630, 1988.
93. Bini A, Mann KG, Kudryk BJ, Schoen FJ: Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 19:1852-1861, 1999.
94. Jeng AY, Chou M, Sawyer WK, Caplan SL, Von Linden-Reed J, Jeune M, Prescott MF: Enhanced expression of matrix metalloproteinase-3, -12, and -13 mRNAs in the aortas of apolipoprotein E-deficient mice with advanced atherosclerosis. Ann N Y Acad Sci 878:555-558, 1999.
95. Prescott MF, Sawyer WK, Von Linden-Reed J, Jeune M, Chou M, Caplan SL, Jeng AY: Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann N Y Acad Sci 878:179-190, 1999.
96. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P: Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol 16:1070-1073, 1996.
97. Perez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, Schlondorff D: Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 12:1369-1382, 2001.
98. Bush E, Maeda N, Kuziel WA, Dawson TC, Wilcox JN, DeLeon H, Taylor WR: CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension. Hypertension 36:360-363, 2000.
99. Schwartz SM, deBlois D, O'Brien ER: The intima. Soil for atherosclerosis and restenosis. Circ Res 77:445-465, 1995.
100. Geary RL, Wong JM, Rossini A, Schwartz SM, Adams LD: Expression profiling identifies 147 genes contributing to a unique primate neointimal smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 22:2010-2016, 2002.
101. Schwartz SM, Heimark RL, Majesky MW: Developmental mechanisms underlying pathology of arteries. Physiol Rev 70:1177-1209, 1990.
102. Majesky MW, Giachelli CM, Reidy MA, Schwartz SM: Rat carotid neointimal smooth muscle cells reexpress a developmentally regulated mRNA phenotype during repair of arterial injury. Circ Res 71:759-768, 1992.
103. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92:1686-1696, 1993.
104. Fu S, Zhao H, Shi J, Abzhanov A, Crawford K, Ohno-Machado L, Zhou J, Du Y, Kuo WP, Zhang J, Jiang M, Jin JG: Peripheral arterial occlusive disease: global gene expression analyses suggest a major role for immune and inflammatory responses. BMC Genomics 9:369, 2008.
105. Weintraub WS: The pathophysiology and burden of restenosis. Am J Cardiol 100:3K-9K, 2007.
106. Nikol S, Huehns TY, Hofling B: Molecular biology and post-angioplasty restenosis. Atherosclerosis 123:17-31, 1996.
107. Caixeta AM, Arie S, Sandoli de Brito Jr. F, Piva de Albuquerque C, Fukushima JT, Garcia DP, Bellotti G, Pileggi F: [Analysis of elastic retraction in the 1st 15minutes after coronary balloon angioplasty]. Arq Bras Cardiol 66:5-9, 1996.
108. Rozenman Y, Gilon D, Welber S, Sapoznikov D, Gotsman MS: Clinical and angiographic predictors of immediate recoil after successful coronary angioplasty and relation to late restenosis. Am J Cardiol 72:1020-1025, 1993.
109. Rodriguez AE, Palacios IF, Fernandez MA, Larribau M, Giraudo M, Ambrose JA: Time course and mechanism of early luminal diameter loss after percutaneous transluminal coronary angioplasty. Am J Cardiol 76:1131-1134, 1995.
110. Casscells W, Engler D, Willerson JT: Mechanisms of restenosis. Tex Heart Inst J 21:68-77, 1994.
111. Pakala R, Willerson JT, Benedict CR: Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 96:2280-2286, 1997.
112. Miano JM, Vlasic N, Tota RR, Stemerman MB: Localization of Fos and Jun proteins in rat aortic smooth muscle cells after vascular injury. Am J Pathol 142:715-724, 1993.
113. Chang CJ, Ko PJ, Hsu LA, Ko YS, Ko YL, Chen CF, Huang CC, Hsu TS, Lee YS, Pang JH: Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis 43:74-84, 2004.
114. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316:1371-1375, 1987.
115. Riessen R, Wight TN, Pastore C, Henley C, Isner JM: Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries. Circulation 93:1141-1147, 1996.
116. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon MB: Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 94:35-43, 1996.
117. Bermejo J, Botas J, Garcia E, Elizaga J, Osende J, Soriano J, Abeytua M, Delcan JL: Mechanisms of residual lumen stenosis after high-pressure stent implantation: a quantitative coronary angiography and intravascular ultrasound study. Circulation 98:112-118, 1998.
118. Dorn GW 2nd: Role of thromboxane A2 in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl 48:42-62, 1997.
119. Rajagopal V, Rockson SG: Coronary restenosis: a review of mechanisms and management. Am J Med 115:547-553, 2003.
120. Kibos A, Campeanu A, Tintoiu I: Pathophysiology of coronary artery in-stent restenosis. Acute Card Care 9:111-119, 2007.
121. Caixeta A, Weisz G: Restenosis and gene polymorphisms. All humans are equal, but some humans are more equal than others. Cardiology 112:260-262, 2009.
122. Petrovic D, Peterlin B: Genetic markers of restenosis after coronary angioplasty and after stent implantation. Med Sci Monit 11:RA127-RA135, 2005.
123. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, et al.: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641-644, 1992.
124. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL: A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94:708-712, 1996.
125. Hamon M, Bauters C, Amant C, McFadden EP, Helbecque N, Lablanche JM, Bertrand ME, Amouyel P: Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty. Circulation 92:296-299, 1995.
126. Koch W, Kastrati A, Mehilli J, Bottiger C, von Beckerath N, Schomig A: Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. Circulation 102:197-202, 2000.
127. Agema WR, Jukema JW, Zwinderman AH, van der Wall EE: A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias. Am Heart J 144:760-768, 2002.
128. Amant C, Bauters C, Bodart JC, Lablanche JM, Grollier G, Danchin N, Hamon M, Richard F, Helbecque N, McFadden EP, Amouyel P, Bertrand ME: D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 96:56-60, 1997.
129. Ribichini F, Steffenino G, Dellavalle A, Matullo G, Colajanni E, Camilla T, Vado A, Benetton G, Uslenghi E, Piazza A: Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation 97:147-154, 1998.
130. Le Tourneau T, Van Belle E, Corseaux D, Vallet B, Lebuffe G, Dupuis B, Lablanche JM, McFadden E, Bauters C, Bertrand ME: Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. J Am Coll Cardiol 33:876-882, 1999.
131. Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Sumida H, Sugiyama S, Kugiyama K, Ogawa H, Ogawa Y, Saito Y, Miyamoto Y, Nakao K: A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 103:65-69, 1998.
132. Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, Fujita T, Ochiai H, Kosuge M, Watanabe Y, Yoshii Y, Kihara M, Kimura K, Ishii M, Umemura S: Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 32:521-526, 1998.
133. Gomma AH, Elrayess MA, Knight CJ, Hawe E, Fox KM, Humphries SE: The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J 23:1955-1962, 2002.
134. Gorchakova O, Koch W, von Beckerath N, Mehilli J, Schomig A, Kastrati A: Association of a genetic variant of endothelial nitric oxide synthase with the 1year clinical outcome after coronary stent placement. Eur Heart J 24:820-827, 2003.
135. Suzuki T, Okumura K, Sone T, Kosokabe T, Tsuboi H, Kondo J, Mukawa H, Kamiya H, Tomida T, Imai H, Matsui H, Hayakawa T: The Glu298Asp polymorphism in endothelial nitric oxide synthase gene is associated with coronary in-stent restenosis. Int J Cardiol 86:71-76, 2002.
136. Tashiro H, Shimokawa H, Sadamatsu K, Aoki T, Yamamoto K: Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coron Artery Dis 12:107-113, 2001.
137. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R: Morphological predictors of restenosis after coronary stenting in humans. Circulation 105:2974-2980, 2002.
138. Francis SE, Camp NJ, Burton AJ, Dewberry RM, Gunn J, Stephens-Lloyd A, Cumberland DC, Gershlick A, Crossman DC: Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty. Heart 86:336-340, 2001.
139. Kastrati A, Koch W, Berger PB, Mehilli J, Stephenson K, Neumann FJ, von Beckerath N, Bottiger C, Duff GW, Schomig A: Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 36:2168-2173, 2000.
140. Koch W, Tiroch K, von Beckerath N, Schomig A, Kastrati A: Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine 24:161-171, 2003.
141. Maines MD: Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 2:2557-2568, 1988.
142. Loboda A, Jazwa A, Grochot-Przeczek A, Rutkowski AJ, Cisowski J, Agarwal A, Jozkowicz A, Dulak J: Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 10:1767-1812, 2008.
143. Dulak J, Deshane J, Jozkowicz A, Agarwal A: Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 117:231-241, 2008.
144. Hill-Kapturczak N, Agarwal A: Haem oxygenase-1-a culprit in vascular and renal damage? Nephrol Dial Transplant 22:1495-1499, 2007.
145. Chen YH, Chau LY, Lin MW, Chen LC, Yo MH, Chen JW, Lin SJ: Heme oxygenase-1 gene promotor microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J 25:39-47, 2004.
146. Exner M, Schillinger M, Minar E, Mlekusch W, Schlerka G, Haumer M, Mannhalter C, Wagner O: Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther 8:433-440, 2001.